ALFA Finder| Revenue growth | 16.6% YoY in Q4; 12.2% in FY26. |
|---|---|
| Margins | Targeting 27-28% EBITDA margins despite infra investments. |
| Demand visibility | Strong volume growth (8.2% in Q4) and rising samples per patient. |
| Management confidence | Confident in sustaining early to mid-teens growth for FY27. |
Growth
Q4 revenue grew 16.6% to ₹703cr; FY26 revenue grew 12.2% to ₹2,763cr. EBITDA margin normalized at 28.3%.
Outlook
FY27 revenue guidance of early to mid-teens (13-15%). Capex planned at ₹100-120cr for labs and radiology.
Risks
Potential supply chain impacts from Middle East conflict affecting reagent imports; wage costs from new Labour Code.
Earnings Call filed with NSE, NSE: LALPATHLAB. Summary written with AI assistance from the document.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹2,039.70
- Market cap
- ₹34,236 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 58.7×Sector 54.5×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Management Change
Dr. Lal Path Labs appointed Ms. Vasuta Agarwal as an additional Non-Executive Independent Director for three years from 4 November 2026. Her appointment is subject to member approval by postal ballot.
- Execution
- 36 months from 04-11-2026
Dr. Lal Pathlabs Capital Structure Change
Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.
- Value
- ₹49.50 Cr
- Execution
- Indicative completion by 31 March 2027, in tranches
Dr. Lal Pathlabs Dividend
Dr. Lal Path Labs approved a Rs 5 per share second interim dividend. Record date is November 11, 2026; payment by December 3, 2026.
Dr. Lal Pathlabs Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 874 Cr (+19.6%), EBITDA Rs 280 Cr (32.1% margin), PAT Rs 194 Cr (+27.5%). Strategy: AI diagnostics, rural GraminFit, M&A.
Dr. Lal Pathlabs Q2 FY27 Results: Net Profit ₹193.9 Cr, Up 27.4% YoY
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹873.9 Cr (+19.6% YoY) and net profit of ₹193.9 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹193.9 Cr · +27.4% YoY
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.